Long-Term Parathyroid Hormone 1-34 Replacement Therapy in Children with Hypoparathyroidism
- PMID: 30470382
- PMCID: PMC6298875
- DOI: 10.1016/j.jpeds.2018.08.010
Long-Term Parathyroid Hormone 1-34 Replacement Therapy in Children with Hypoparathyroidism
Abstract
Objective: To determine whether multiple daily injections of parathyroid hormone (PTH) 1-34 are safe and effective as long-term therapy for children with hypoparathyroidism.
Study design: Linear growth, bone accrual, renal function, and mineral homeostasis were studied in a long-term observational study of PTH 1-34 injection therapy in 14 children.
Methods: Subjects were 14 children with hypoparathyroidism attributable to autoimmune polyglandular syndrome type 1 (N = 5, ages 7-12 years) or calcium receptor mutation (N = 9, ages 7-16 years). Mean daily PTH 1-34 dose was 0.75 ± 0.15 µg/kg/day. Treatment duration was 6.9 ± 3.1 years (range 1.5-10 years). Patients were evaluated semiannually at the National Institutes of Health Clinical Center.
Results: Mean height velocity and lumbar spine, whole body, and femoral neck bone accretion velocities were normal throughout the study. In the first 2 years, distal one-third radius bone accrual velocity was reduced compared with normal children (P < .003). Serum alkaline phosphatase correlated with PTH 1-34 dose (P < .006) and remained normal (235.3 ± 104.8 [SD] U/L, N: 51-332 U/L). Mean serum and 24-hour urine calcium levels were 2.05 ± 0.11 mmol/L (N: 2.05-2.5 mmol/L) and 6.93 ± 1.3 mmol/24 hour (N: 1.25-7.5 mmol/24 hour), respectively-with fewer high urine calcium levels vs baseline during calcitriol and calcium treatment (P < .001). Nephrocalcinosis progressed in 5 of 12 subjects who had repeated renal imaging although renal function remained normal.
Conclusions: Twice-daily or thrice-daily subcutaneous PTH 1-34 injections provided safe and effective replacement therapy for up to 10 years in children with hypoparathyroidism because of autoimmune polyglandular syndrome type 1 or calcium receptor mutation.
Keywords: ADH; APECED; APS-1; PTH 1-34; Vitamin D; autosomal dominant hypocalcemia; calcium receptor; hypocalcemia; hypomagnesemia; teriparatide.
Published by Elsevier Inc.
Figures
Similar articles
-
Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium.J Clin Endocrinol Metab. 2010 Jun;95(6):2680-8. doi: 10.1210/jc.2009-2464. Epub 2010 Apr 14. J Clin Endocrinol Metab. 2010. PMID: 20392870 Free PMC article. Clinical Trial.
-
Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.Clin Ther. 2014 May;36(5):722-36. doi: 10.1016/j.clinthera.2014.04.001. Epub 2014 May 5. Clin Ther. 2014. PMID: 24802860 Clinical Trial.
-
Therapy with PTH 1-34 or calcitriol and calcium in diverse etiologies of hypoparathyroidism over 27 years at a single tertiary care center.Bone. 2021 Aug;149:115977. doi: 10.1016/j.bone.2021.115977. Epub 2021 Apr 28. Bone. 2021. PMID: 33932619
-
Advances in the treatment of hypoparathyroidism with PTH 1-34.Bone. 2019 Mar;120:535-541. doi: 10.1016/j.bone.2018.09.018. Epub 2018 Sep 21. Bone. 2019. PMID: 30243992 Review.
-
Hypoparathyroidism.Best Pract Res Clin Endocrinol Metab. 2012 Aug;26(4):517-22. doi: 10.1016/j.beem.2012.01.004. Epub 2012 May 31. Best Pract Res Clin Endocrinol Metab. 2012. PMID: 22863393 Review.
Cited by
-
Exploring Chronic Hypocalcemia: Insights into Autoimmune Polyglandular Syndrome Type 1-A Case Study and Literature Review.J Clin Med. 2024 Apr 18;13(8):2368. doi: 10.3390/jcm13082368. J Clin Med. 2024. PMID: 38673639 Free PMC article. Review.
-
Continuous Subcutaneous Delivery of rhPTH(1-84) and rhPTH(1-34) by Pump in Adults With Hypoparathyroidism.J Endocr Soc. 2024 Mar 29;8(5):bvae053. doi: 10.1210/jendso/bvae053. eCollection 2024 Mar 12. J Endocr Soc. 2024. PMID: 38562130 Free PMC article.
-
Case Report: Calcium sensing receptor gene gain of function mutations: a case series and report of 2 novel mutations.Front Endocrinol (Lausanne). 2023 Aug 15;14:1215036. doi: 10.3389/fendo.2023.1215036. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37654565 Free PMC article.
-
Use of rhPTH(1-84) for hypoparathyroidism during early pregnancy and lactation.Endocrinol Diabetes Metab Case Rep. 2023 Jun 19;2023(2):22-0401. doi: 10.1530/EDM-22-0401. Print 2023 Jun 1. Endocrinol Diabetes Metab Case Rep. 2023. PMID: 37335755 Free PMC article.
-
A Rare Case of Autoimmune Polyendocrinopathy-candidiasis-ectodermal Dystrophy Syndrome: Dental Perspective on Diagnosis and Management.Int J Clin Pediatr Dent. 2023 Jan-Feb;16(1):139-146. doi: 10.5005/jp-journals-10005-2496. Int J Clin Pediatr Dent. 2023. PMID: 37020766 Free PMC article.
References
-
- Bollerslev J, Rejnmark L, Marococci C, Shoback D, Sitges-Serra A, Van Biesen W, et al. European Society of Endocrinology Clinical Guideline: Treatment of Chronic Hypoparathyroidism in adults. European Journal of Endocrinology 2015;173: G1–G20. - PubMed
-
- Mancilla EE, De Luca F, Ray K, Winer KK, Fan GF. A Ca (2+) sensing receptor mutation causes hypoparathyroidism by increasing receptor sensitivity to CA2+ and maximal signal transduction. Pediatri Res. 1997; 42:443–7 - PubMed
-
- Winer KK, Yanovski JA, Sarani B, Cutler GB Jr. A randomized, crossover trial of once-daily versus twice-daily human parathyroid hormone 1–34 in the treatment of hypoparathyroidism. J Clin Endocrinol Metab 1998; 83:3480–3486. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous